 |
|
Liver Cancer Trial Results
1. Sorafenib Increases the Risk of High Blood Pressure
(Posted: 04/02/2008) - Combined data from nine studies showed that patients receiving the standard amount of sorafenib (Nexavar®), an anticancer drug that interferes with a tumor's blood supply, run a significant risk of high blood pressure (hypertension), according to the February 2008 Lancet Oncology.
2. Sorafenib for Advanced Liver Cancer Increases Survival
(Posted: 06/13/2007, Reviewed: 07/30/2008) - The targeted drug sorafenib (Nexavar®) has improved the survival of patients with advanced liver cancer, according to the July 24, 2008, New England Journal of Medicine.
3. Chemoembolization May Help Some Patients with Inoperable Liver Cancer
(Posted: 06/06/2002, Reviewed: 03/15/2006) - A procedure that uses the drug doxorubicin to help block blood flow to liver tumors improved survival in some patients with inoperable liver cancer, researchers reported in the May 18, 2002, issue of the British journal the Lancet.
|
|
|
